Sol-Gel Technologies (NASDAQ:SLGL) versus Hypermarcas (OTCMKTS:HYPMY) Head-To-Head Contrast

Hypermarcas (OTCMKTS:HYPMY) and Sol-Gel Technologies (NASDAQ:SLGL) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

Insider & Institutional Ownership

26.2% of Sol-Gel Technologies shares are owned by institutional investors. 66.5% of Sol-Gel Technologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Hypermarcas and Sol-Gel Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Hypermarcas	19.77%	12.68%	6.78%
Sol-Gel Technologies	-910.14%	-44.05%	-36.96%

Valuation & Earnings

This table compares Hypermarcas and Sol-Gel Technologies”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hypermarcas	$1.38 billion	1.96	$213.10 million	$0.50	7.66
Sol-Gel Technologies	$19.39 million	10.76	-$6.13 million	($5.64)	-11.31

Hypermarcas has higher revenue and earnings than Sol-Gel Technologies. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than Hypermarcas, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Hypermarcas has a beta of 0.78, suggesting that its stock price is 22% less volatile than the S&P 500. Comparatively, Sol-Gel Technologies has a beta of 1.25, suggesting that its stock price is 25% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Hypermarcas and Sol-Gel Technologies, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hypermarcas	0	1	0	1	3.00
Sol-Gel Technologies	1	0	4	2	3.00

Sol-Gel Technologies has a consensus target price of $197.50, suggesting a potential upside of 209.51%. Given Sol-Gel Technologies’ higher possible upside, analysts plainly believe Sol-Gel Technologies is more favorable than Hypermarcas.

About Hypermarcas

Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, Max Sulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands. The company also provides sun protection and moisturizing skin care products under the Mantecorp Skincare brands; similar products under the Doralgina, Dropy D, balance, Flavonid, histamin, NeoFresh, neolefrin, Neochemistry Vitamins, Neosorum, and Torsilax brand names; and consumer health products under the Apracur, Benegrip, Buscopan, Coristina D Pro, Engov, Epocler, Estomazil, and Neosaldina brands, as well as similar and generic drugs under the Neo Química brand. In addition, it offers nutritional and vitamin supplement products under the Tamarine, Vitasay, Biotônico Fontoura, and Zero-Cal brands; and generic medicines under the Hydroxyzine, Sodium Diclofenac, Dipyron, Ibuprofen, Losartan Potassium, Mal Dexchlorpheniramine, Naproxene, Paracetamol, Simethicon, Loratadine, Omeprazole, Tadalaphyl, and Desogestrel brand names. The company was formerly known as Hypermarcas S.A. and changed its name to Hypera S.A. in February 2018. Hypera S.A. was founded in 2001 and is headquartered in São Paulo, Brazil.

About Sol-Gel Technologies

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.